Search results for: “keytruda”
-
Blog
Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs
Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…
-
Blog
Recent FDA Announcements Herald Advances in Personalized Approaches Against Cancer
Two tumor-profiling tests recently authorized by the FDA enable doctors to tailor their treatments more effectively to…
-
Blog
Checkpoint Immunotherapy Approved for Patients with Stomach, Gastroesophageal, and Liver Cancer
Previously treated patients with these cancer types can now receive anti-PD-1 immunotherapy; nivolumab for HCC and pembrolizumab…
-
Blog
Nivolumab Approved for Patients with Chemotherapy-Resistant, Metastatic, MSI-H Colorectal Cancer
Nivolumab becomes second checkpoint immunotherapy approved for colorectal cancer
-
Blog
Immunotherapy Makes History with Latest Cancer Approval
The FDA’s biomarker-based approval of Keytruda was the first of its kind
-
Blog
AACR17 Update: Checkpoints, Vaccines, and the Power of Prediction
Day 3 at AACR17 highlighted the importance of immune memory and personalized approaches…
-
Blog
Dax Bykerk’s Immunotherapy Story
Melanoma | Diagnosed Age 34 It takes about an hour and a half at best, and then you’re… -
Blog
Henrik Vad Madsen’s Immunotherapy Story
Melanoma | Diagnosed 2003 My approach was to say: I have cancer, but I want to have a… -
Blog
Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer